We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Gastrointestinal PCR Assay Offers Rapid, Culture-Free Pathogen Identification

By LabMedica International staff writers
Posted on 17 Apr 2023
Print article
Image: The LiquidArray Gastrointestinal assay detects up to 26 pathogens from stool samples in a two-well format (Photo courtesy of Bruker)
Image: The LiquidArray Gastrointestinal assay detects up to 26 pathogens from stool samples in a two-well format (Photo courtesy of Bruker)

Gastroenteritis involves inflammation of the stomach and intestines' lining, typically characterized by diarrhea and/or vomiting. Gastrointestinal pathogens can cause life-threatening diseases, especially among children, immunosuppressed individuals, and the elderly. While most cases resolve within days, severe or persistent cases may necessitate hospitalization. Testing stool samples for potential causative agents—bacteria, viruses, parasites, and toxins—creates a substantial diagnostic burden in healthcare facilities. Now, a new syndromic panel for gastrointestinal infections that identifies 26 gastroenteritis-causing pathogens, including bacteria, viruses, parasites, and related toxins, aims to streamline routine procedures and enhance diagnostic efficiency.

Bruker Corporation’s (Billerica, MA, USA) new LiquidArray Gastrointestinal is a syndromic panel for gastrointestinal infections. The assay employs LiquidArray, a next-generation multiplexing technology, to detect up to 26 pathogens from stool samples using a two-well format that supports routine laboratory throughput needs. Introduced on the high-precision FluoroCycler XT thermocycler, LiquidArray merges innovative probe and thermocycling technologies with results-at-a-glance visualization for simultaneous analysis of multiple targets from a single sample. The integrated FluoroSoftware XT-IVD generates easy-to-understand results, expediting clinical decisions.

LiquidArray Gastrointestinal is validated on the GenoXtract fleXT, a dependable, automated system for extracting nucleic acid from patient samples and setting up PCR plates. Barcode-supported robotic sorting minimizes manual intervention. Validated processing of LiquidArray Gastrointestinal on the GenoXtract fleXT offers a convenient walk-away solution tailored for dynamic laboratory environments. This equips high-throughput clinical labs with a fully integrated workflow from sample to result. The test is validated for use with stool samples, and a stool buffer developed for LiquidArray Gastrointestinal enables stabilization and storage of samples to be tested. The kit includes reagents for up to 48 reactions.

“The new LiquidArray Gastrointestinal is a next-generation syndromic panel with amazing pathogen coverage. It is ideal for laboratories which are interested in a broad screening approach to detect most pathogens in one run,” said Dr. Wolfgang Pusch, President of the Bruker Microbiology & Infection Diagnostics division.

Related Links:
Bruker Corporation 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Coagulation Analyzer
CS-2400

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.